BioLamina Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
120
- Latest Deal Type
-
Debt
- Latest Deal Amount
-
$23.2M
- Investors
-
6
BioLamina General Information
Description
Developer of cell culture reagents designed to imitate the natural, cell-specific matrix interaction. The company's reagents provide assistance in culturing primary cells, preparing antibiotics, and cell development tools, such as stem cells, enabling doctors to achieve clinically compliant cell therapies and research outcomes to improve cell functionality.
Contact Information
Website
www.biolamina.comCorporate Office
- Lofstroms Alle 5 A
- 172 66 Sundbyberg
- Sweden
Corporate Office
- Lofstroms Alle 5 A
- 172 66 Sundbyberg
- Sweden
BioLamina Timeline
BioLamina Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Debt - General | 16-Apr-2026 | $23.2M | Completed | Generating Revenue | ||
| 7. Later Stage VC | 12-Sep-2023 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 31-Dec-2021 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 31-Dec-2020 | Completed | Generating Revenue | |||
| 4. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 3. Grant | 07-Nov-2018 | Completed | Generating Revenue | |||
| 2. Later Stage VC | 01-Jan-2017 | $1.19M | $3.52M | Completed | Generating Revenue | |
| 1. Later Stage VC | 13-Nov-2013 | $2.32M | $2.32M | Completed | Generating Revenue |
BioLamina Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference | ||||||||
| Preference | ||||||||
| Preference | ||||||||
| Preference | ||||||||
| Preference | 19,400 | $68.04 | $68.04 | 1x | $68.04 | 8.36% | ||
| Preference | 13,774 | $136.89 | $136.89 | 1x | $136.89 | 5.94% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
BioLamina Comparisons
Industry
Financing
Details
BioLamina Competitors (10)
One of BioLamina’s 10 competitors is PeproTech, a Corporate Backed or Acquired company based in Cranbury, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| PeproTech | Corporate Backed or Acquired | Cranbury, NJ | ||||
| Cardiff Oncology | Formerly Angel backed | San Diego, CA | ||||
| Illumina | Formerly VC-backed | San Diego, CA | ||||
| Meridian Bioscience | Private Equity-Backed | Cincinnati, OH | ||||
| Proteintech | Corporation | Rosemont, IL |
BioLamina Patents
BioLamina Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3810758-A1 | Methods and compositions for producing retinal pigment epithelium cells | Active | 20-Jun-2018 | ||
| EP-3810758-B1 | Methods and compositions for producing retinal pigment epithelium cells | Active | 20-Jun-2018 | ||
| EP-4234024-A2 | Methods and compositions for producing retinal pigment epithelium cells | Active | 20-Jun-2018 | ||
| EP-4234024-A3 | Methods and compositions for producing retinal pigment epithelium cells | Active | 20-Jun-2018 | ||
| EP-4234024-B1 | Methods and compositions for producing retinal pigment epithelium cells | Active | 20-Jun-2018 | C12N5/0621 |
BioLamina Signals
BioLamina Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Lauxera Capital Partners | Growth/Expansion | Minority | ||
| Northislet | Growth/Expansion | Minority | ||
| Vinnova | Government | |||
| Zentrales Innovationsprogramm Mittelstand | Government | |||
| Bure Equity | PE/Buyout | Minority |
BioLamina FAQs
-
When was BioLamina founded?
BioLamina was founded in 2008.
-
Where is BioLamina headquartered?
BioLamina is headquartered in Sundbyberg, Sweden.
-
What is the size of BioLamina?
BioLamina has 120 total employees.
-
What industry is BioLamina in?
BioLamina’s primary industry is Biotechnology.
-
Is BioLamina a private or public company?
BioLamina is a Private company.
-
What is BioLamina’s current revenue?
The current revenue for BioLamina is .
-
How much funding has BioLamina raised over time?
BioLamina has raised $50.2M.
-
Who are BioLamina’s investors?
Lauxera Capital Partners, Northislet, Vinnova, Zentrales Innovationsprogramm Mittelstand, and Bure Equity are 5 of 6 investors who have invested in BioLamina.
-
Who are BioLamina’s competitors?
PeproTech, Cardiff Oncology, Illumina, Meridian Bioscience, and Proteintech are some of the 10 competitors of BioLamina.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process